Sutton Disease II
Links shared publicly online about this topic
Alzheimer's Disease Part II
alzheimersdisease02.blogspot.com — “Alzheimer's Disease Part II” View full resource at alzheimersdisease02.blogspot.com
Most Recently Shared on October 10, 2011 at 12:12 am By:
Alzheimer's Disease Part II - What Causes Alzheimer's Disease? http://t.co/33A2NjVB
Mucopolysaccharidosis Type II: eMedicine Pediatrics: Genetics and Metabolic Disease
emedicine.medscape.com — “Overview: Hunter syndrome, or mucopolysaccharidosis type II (MPS II), is a member of a group of inherited metabolic disorders collectively termed mucopolysaccharidoses (MPSs). The MPSs are caused by a deficiency of lysosomal enzymes required for the degradation ...” View full resource at emedicine.medscape.com
Most Recently Shared on July 15, 2009 at 9:36 pm By:
Medscape Pediatrics Health Site and Pediatrics
Mucopolysaccharidosis Type II article over at eMedicine has been updated. http://bit.ly/VTYYW #genetics #pediatrics #health #medicine
Phase II Study Of An Oral Therapy For Gaucher Disease Yields Positive Results
medicalnewstoday.com — “Gaucher disease, a rare enzyme deficiency disorder, is one of many conditions with few approved treatment options for patients. In a” View full resource at medicalnewstoday.com
Most Recently Shared on May 5, 2010 at 12:18 pm By:
MNT Clinical Trials Health News
Phase II Study Of An Oral Therapy For Gaucher Disease Yields Positive Results http://mnt.to/3C85 #clinicaltrials
Can Social Networks Cure Disease? Part II
networkedblogs.com — “Can Social Networks Cure Disease? Part II” View full resource at networkedblogs.com
Most Recently Shared on April 20, 2012 at 8:28 pm By:
Mark Hyman, M.D. Doctor and Physician
Can Social Networks Cure Disease? Part II http://t.co/j3iKq5n4
The Pediatric Airway in Health and Disease II | VEOMED
veomed.com — “The Pediatric Airway in Health and Disease II | VEOMED” View full resource at veomed.com
Most Recently Shared on March 15, 2010 at 10:39 pm By:
The Pediatric Airway in Health and Disease II by The Pediatric Emergency Medicine Resource Albany Medical College http://ow.ly/1lleV
Glycogen Storage Disease, Type II (Pompe Disease): eMedicine Endocrinology
emedicine.medscape.com — “Overview: A glycogen storage disease (GSD) is the result of an enzyme defect. These enzymes normally catalyze reactions that ultimately convert glycogen compounds to monosaccharides, of which glucose is the predominant component. Enzyme deficiency results in glycogen ...” View full resource at emedicine.medscape.com
Most Recently Shared on May 5, 2010 at 7:01 pm By:
Type II glycogen storage disease, or Pompe disease, is a result of acid maltase deficiency. More about type II GSD. http://bit.ly/bQYTVx
Launch Of First Phase II Trial Of Heart Disease Treatment For Duchenne Muscular Dystrophy
medicalnewstoday.com — “Kennedy Krieger Institute has announced the launch of a first-of-its-kind, phase II clinical trial to investigate a treatment for heart disease in individuals with Duchenne muscular dystrophy (DM” View full resource at medicalnewstoday.com
Most Recently Shared on October 14, 2010 at 1:05 pm By:
Launch Of First Phase II Trial Of Heart Disease Treatment For Duchenne Muscular Dystrophy http://mnt.to/3L9R #menshealth
A phase II trial of huperzine A in mild to moderate Alzheimer disease
neurology.org — “A phase II trial of huperzine A in mild to moderate Alzheimer disease” View full resource at neurology.org
Most Recently Shared on April 21, 2011 at 6:55 pm By:
Neurology Journal Medical Journal and Neurology
A phase II trial of huperzine A in mild to moderate Alzheimer disease http://bit.ly/gQ40CY #neurology
Phase II study of an oral therapy for Gaucher disease yields positive results
physorg.com — “Gaucher disease, a rare enzyme deficiency disorder, is one of many conditions with few approved treatment options for patients. In a study published online today in Blood, the journal of the American Society of Hematology, researchers present positive results of a Phase II clinical trial of eliglustat ...” View full resource at physorg.com
Most Recently Shared on May 3, 2010 at 9:40 pm By:
PhysOrg Health News Health News
Phase II study of an oral therapy for Gaucher disease yields positive results http://tw.physorg.com/192124667
NeuroDerm Announces Positive Results Of A Phase II Study Of ND0611 Dermal Patch In Patients With Parkinson's Disease
medicalnewstoday.com — “NeuroDerm, Ltd. announced today the results of a Phase I/II safety and pharmacokinetic trial of ND0611, administered as an adjunct therapy to Sinemet®, Sinemet® CR or Stalevo®, in pati” View full resource at medicalnewstoday.com
Most Recently Shared on November 10, 2011 at 11:05 am By:
MNT Parkinson's News Health News
NeuroDerm Announces Positive Results Of A Phase II Study Of ND0611 Dermal Patch In Patients With Parkinson's Disease http://t.co/izZihbsC
TxCell Receives Approval For Extension Of Phase I/II Clinical Trial In Crohn's Disease
medicalnewstoday.com — “TxCell SA, a biotechnology company developing cell-based immunotherapies for the treatment of severe chronic inflammatory diseases with high unmet medical need, announces today the approval by AFS” View full resource at medicalnewstoday.com
Most Recently Shared on May 18, 2011 at 4:05 pm By:
TxCell Receives Approval For Extension Of Phase I/II Clinical Trial In Crohn's Disease http://mnt.to/3W3D #crohns #ibd
Symposier - Anatomic Basic of Echocardiography in Congenital Heart Disease-II
symposier.com — “Uploaded and Shared in Youtube by: ignousohs School of Health Sciences:Post Graduate Diploma in Clinical Cardiology (PGDCC):MCC-002 Fundamentals of Cardiovascular System-II” View full resource at symposier.com
Most Recently Shared on March 4, 2010 at 3:37 am By:
Symposier Cardiology Cardiology and Health Business
Anatomic Basic of Echocardiography in Congenital Heart Disease. http://bit.ly/aPNTBA http://bit.ly/cxZ1MX
Polyglandular Autoimmune Syndrome, Type II: eMedicine Endocrinology
emedicine.medscape.com — “Overview: Polyglandular autoimmune syndrome type II (PGA-II) is the most common of the immunoendocrinopathy syndromes. It is characterized by the obligatory occurrence of autoimmune Addison's disease in combination with thyroid autoimmune diseases and/or type 1 diabetes mellitus ...” View full resource at emedicine.medscape.com
Most Recently Shared on April 14, 2010 at 3:19 am By:
Susan Scroggins Active Health Library and Health Advocate
Polyglandular autoimmune syndrome type 2 is characterized by Addison's disease plus thyroid autoimmune disease...http://bit.ly/dhsev0
ThromboGenics Positive Microplasmin Phase II Data Published In Ophthalmology
medicalnewstoday.com — “ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces tha” View full resource at medicalnewstoday.com
Most Recently Shared on February 10, 2010 at 3:09 pm By:
ThromboGenics Positive Microplasmin Phase II Data Published In Ophthalmology http://mnt.to/3xrc #eyehealth
Angiotensin II Antagonists In Paroxysmal Atrial Fibrillation, Results From The ANTIPAF Trial
medicalnewstoday.com — “Atrial fibrillation (AF) is the most common cardiac arrhythmia, affecting about 7 million people in Europe. It is a progressive chronic disease in which episodes become more frequent and long-last” View full resource at medicalnewstoday.com
Most Recently Shared on September 1, 2010 at 11:40 am By:
Hisham Rana, MD Doctor and Physician
News: Angiotensin II antagonists in paroxysmal atrial fibrillation, results from the ANTIPAF trial http://bit.ly/dnPNNg - #health
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
Kyle J.Norton
Health Researcher and Article Writer. Master in Mathematics and BA in World Literature and Literary criticism. Always follow back.
-
Medscape Pediatrics
Latest medical news, articles, and features from Medscape Pediatrics
-
MNT Clinical Trials
The latest clinical trials news published daily. Articles from research centers, universities and prestigious journals.
Advertisement
